Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc.

Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer Management


Release Date: March 30, 2018
Expiration Date: March 30, 2019
Media: Internet - based

 

Activity Overview

This online activity will feature a comprehensive overview of noteworthy lung cancer data presented at major society meetings, and will include expert discussions on the clinical application of these data and the future direction of the lung cancer treatment landscape.

The format for today’s Year in Review will include 3 modules of didactic presentations and interactive discussion among our panel of experts and provide insight into recent advances in immunotherapy, targeted therapy, and molecular testing/personalized medicine.

Acknowledgement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc.

CME Activity Table of Contents

  • Module 1: Immunotherapy
  • Module 2: Targeted Therapy
  • Module 3: Molecular Testing/Personalized Medicine

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists and nurses involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Discuss testing methods used to facilitate the application of personalized treatment strategies among patients with advanced forms of lung cancer in multiple lines of care
  • Explain recent evidence from clinical trials conducted in the setting of advanced non-small cell lung cancer (NSCLC)
  • Determine the applicability of recent trial results in the context of real-world clinical scenarios commonly encountered in care for patients with lung cancer
  • Identify planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced NSCLC management

Faculty, Staff, and Planners' Disclosures

Moderator

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Research Grants: AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Liquid Genomics, Merck, Mirati, Novartis, Peregrine, Pfizer, Roche Diagnostics, Synta, Trovagene

Faculty

Mark Kris, MD
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosure: Research Grants: AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Liquid Genomics, Merck, Mirati, Novartis, Peregrine, Pfizer, Roche Diagnostics, Synta, Trovagene

Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosure: Consultant: Roche, AstraZeneca, Novartis, Merck, Lilly, Bristol-Myers Squibb, Pfizer, Gritstone Oncology, ARMO Biosciences.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By